Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 26, Number 7—July 2020
Synopsis

Macrolide-Resistant Mycoplasma pneumoniae Infections in Pediatric Community-Acquired Pneumonia

Yu-Chin Chen1, Wei-Yun Hsu1, and Tu-Hsuan Chang1Comments to Author 
Author affiliations: Chi-Mei Medical Center, Chiali, Tainan, Taiwan (Y.-C. Chen); Chi-Mei Medical Center, Tainan, Taiwan (W.-Y. Hsu, T.-H. Chang)

Main Article

Table

Characteristics of the eligible studies of macrolide resistance and Mycoplasma pneumoniae infections.

Author Study period Country Mutations detected Disease entity Case no. Resistance
Chen (8) 2014–2016 China A2063G, A2064G CAP, inpatient 136 60%
Ma (9) 2010–2011 China A2063G, A1290G CAP, inpatient 57 63%
Xin (10) 2004–2005 China A2063G, A2064G CAP, inpatient 64 59%
Yuan (11) 2016 China A2063G, A2064G, C2617G CAP, inpatient 120 82%
Zhou (7) 2009–2010 China A2063G, A2063T, A2064G CAP, inpatient 235 88%
Cheong (12) 2011–2013 HK A2063G CAP, inpatient 93 27%
Lung (13) 2010–2013 HK A2063G CAP, inpatient 48 71%
Cardinale (14) 2010 Italy A2063G, A2064G CAP, inpatient 46 17%
Akashi (15) 2016–2017 Japan A2063G, A2064G CAP, mixed 222 65%
Ishiguro (16) 2013–2015 Japan A2063G CAP, mixed 109 54%
Kawai (17) 2005–2010 Japan A2063G, A2064G CAP, mixed 29 72%
Kawai (18) 2005–2012 Japan A2063G, A2064G CAP, mixed 188 80%
Matsubara (19) 2002–2006 Japan A2063G, A2064G CAP, NS 69 32%
Miyashita (20) 2008–2011 Japan A2063G, A2064G CAP, NS 71 59%
Okada (21) 2011 Japan A2063G, A2064G CAP, mixed 202 87%
Kim JH (22) 2011–2015 Korea A2063G CAP, inpatient 250 74%
Kim YJ (23) 2010–2015 Korea A2063G CAP, inpatient 107 10%
Lee (24) 2015 Korea A2063G CAP, mixed 94 13%
Seo (25) 2011 Korea A2063G CAP, inpatient 95 52%
Yoo (26) 2011 Korea A2063G CAP, mixed 91 30%
Yoon (27) 2010–2015 Korea A2063G CAP, inpatient 116 71%
Wu HM (28) 2011 Taiwan A2063G CAP, inpatient 73 12%
Wu PS (29) 2010–2011 Taiwan A2063G CAP, inpatient 60 23%
Yang (30) 2010–2017 Taiwan A2063G, A2063T, A2064G CAP, mixed 471 24%

*CAP, community acquired pneumonia; HK, Hong Kong; NS, not specified.

Main Article

References
  1. Jain  S, Williams  DJ, Arnold  SR, Ampofo  K, Bramley  AM, Reed  C, et al.; CDC EPIC Study Team. Community-acquired pneumonia requiring hospitalization among U.S. children. N Engl J Med. 2015;372:835–45. DOIPubMedGoogle Scholar
  2. Shin  EJ, Kim  Y, Jeong  J-Y, Jung  YM, Lee  M-H, Chung  EH. The changes of prevalence and etiology of pediatric pneumonia from National Emergency Department Information System in Korea, between 2007 and 2014. Korean J Pediatr. 2018;61:291–300. DOIPubMedGoogle Scholar
  3. Hsieh  YC, Tsao  KC, Huang  CG, Tong  S, Winchell  JM, Huang  YC, et al. Life-threatening pneumonia caused by macrolide-resistant Mycoplasma pneumoniae. Pediatr Infect Dis J. 2012;31:208–9. DOIPubMedGoogle Scholar
  4. Wood  PR, Hill  VL, Burks  ML, Peters  JI, Singh  H, Kannan  TR, et al. Mycoplasma pneumoniae in children with acute and refractory asthma. Ann Allergy Asthma Immunol. 2013;110:328–34.e1.
  5. Pereyre  S, Goret  J, Bébéar  C. Mycoplasma pneumoniae: current knowledge on macrolide resistance and treatment. Front Microbiol. 2016;7:974. DOIPubMedGoogle Scholar
  6. Meyer Sauteur  PM, Unger  WW, Nadal  D, Berger  C, Vink  C, van Rossum  AM. Infection with and carriage of Mycoplasma pneumoniae in children. Front Microbiol. 2016;7:329. DOIPubMedGoogle Scholar
  7. Zhou  Y, Zhang  Y, Sheng  Y, Zhang  L, Shen  Z, Chen  Z. More complications occur in macrolide-resistant than in macrolide-sensitive Mycoplasma pneumoniae pneumonia. Antimicrob Agents Chemother. 2014;58:1034–8. DOIPubMedGoogle Scholar
  8. Chen  Y, Tian  WM, Chen  Q, Zhao  HY, Huang  P, Lin  ZQ, et al. [Clinical features and treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children]. Zhongguo Dang Dai Er Ke Za Zhi. 2018;20:629–34.PubMedGoogle Scholar
  9. Ma  Z, Zheng  Y, Deng  J, Ma  X, Liu  H. Characterization of macrolide resistance of Mycoplasma pneumoniae in children in Shenzhen, China. Pediatr Pulmonol. 2014;49:695–700. DOIPubMedGoogle Scholar
  10. Xin  D-L, Wang  S, Han  X, Ma  S-J, Chen  X-G. Clinical characteristics of children with macrolide-resistant Mycoplasma pneumoniae pneumonia [in Chinese]. J Appl Clin Pediatr. 2010;16:1213–5.
  11. Yuan  C, Min  FM, Ling  YJ, Li  G, Ye  HZ, Pan  JH, et al. Clinical characteristics and antibiotic resistance of Mycoplasma pneumoniae pneumonia in hospitalized Chinese children. Comb Chem High Throughput Screen. 2018;21:749–54. DOIPubMedGoogle Scholar
  12. Cheong  KN, Chiu  SS, Chan  BW, To  KK, Chan  EL, Ho  PL. Severe macrolide-resistant Mycoplasma pneumoniae pneumonia associated with macrolide failure. J Microbiol Immunol Infect. 2016;49:127–30. DOIPubMedGoogle Scholar
  13. Lung  DC, Yip  EK, Lam  DS, Que  TL. Rapid defervescence after doxycycline treatment of macrolide-resistant Mycoplasma pneumoniae-associated community-acquired pneumonia in children. Pediatr Infect Dis J. 2013;32:1396–9. DOIPubMedGoogle Scholar
  14. Cardinale  F, Chironna  M, Chinellato  I, Principi  N, Esposito  S. Clinical relevance of Mycoplasma pneumoniae macrolide resistance in children. J Clin Microbiol. 2013;51:723–4. DOIPubMedGoogle Scholar
  15. Akashi  Y, Hayashi  D, Suzuki  H, Shiigai  M, Kanemoto  K, Notake  S, et al. Clinical features and seasonal variations in the prevalence of macrolide-resistant Mycoplasma pneumoniae. J Gen Fam Med. 2018;19:191–7. DOIPubMedGoogle Scholar
  16. Ishiguro  N, Koseki  N, Kaiho  M, Ariga  T, Kikuta  H, Togashi  T, et al.; Hokkaido Pediatric Respiratory Infection Study Group. Therapeutic efficacy of azithromycin, clarithromycin, minocycline and tosufloxacin against macrolide-resistant and macrolide-sensitive Mycoplasma pneumoniae pneumonia in pediatric patients. PLoS One. 2017;12:e0173635. DOIPubMedGoogle Scholar
  17. Kawai  Y, Miyashita  N, Yamaguchi  T, Saitoh  A, Kondoh  E, Fujimoto  H, et al. Clinical efficacy of macrolide antibiotics against genetically determined macrolide-resistant Mycoplasma pneumoniae pneumonia in paediatric patients. Respirology. 2012;17:354–62. DOIPubMedGoogle Scholar
  18. Kawai  Y, Miyashita  N, Kubo  M, Akaike  H, Kato  A, Nishizawa  Y, et al. Therapeutic efficacy of macrolides, minocycline, and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae pneumonia in pediatric patients. Antimicrob Agents Chemother. 2013;57:2252–8. DOIPubMedGoogle Scholar
  19. Matsubara  K, Morozumi  M, Okada  T, Matsushima  T, Komiyama  O, Shoji  M, et al. A comparative clinical study of macrolide-sensitive and macrolide-resistant Mycoplasma pneumoniae infections in pediatric patients. J Infect Chemother. 2009;15:380–3. DOIPubMedGoogle Scholar
  20. Miyashita  N, Kawai  Y, Akaike  H, Ouchi  K, Hayashi  T, Kurihara  T, et al.; Atypical Pathogen Study Group. Macrolide-resistant Mycoplasma pneumoniae in adolescents with community-acquired pneumonia. BMC Infect Dis. 2012;12:126. DOIPubMedGoogle Scholar
  21. Okada  T, Morozumi  M, Tajima  T, Hasegawa  M, Sakata  H, Ohnari  S, et al. Rapid effectiveness of minocycline or doxycycline against macrolide-resistant Mycoplasma pneumoniae infection in a 2011 outbreak among Japanese children. Clin Infect Dis. 2012;55:1642–9. DOIPubMedGoogle Scholar
  22. Kim  JH, Kim  JY, Yoo  CH, Seo  WH, Yoo  Y, Song  DJ, et al. Macrolide resistance and its impacts on M. pneumoniae pneumonia in children: comparison of two recent epidemics in Korea. Allergy Asthma Immunol Res. 2017;9:340–6. DOIPubMedGoogle Scholar
  23. Kim  YJ, Shin  KS, Lee  KH, Kim  YR, Choi  JH. Clinical characteristics of macrolide-resistant Mycoplasma pneumoniae from children in Jeju. J Korean Med Sci. 2017;32:1642–6. DOIPubMedGoogle Scholar
  24. Lee  E, Cho  HJ, Hong  SJ, Lee  J, Sung  H, Yu  J. Prevalence and clinical manifestations of macrolide resistant Mycoplasma pneumoniae pneumonia in Korean children. Korean J Pediatr. 2017;60:151–7. DOIPubMedGoogle Scholar
  25. Seo  YH, Kim  JS, Seo  SC, Seo  WH, Yoo  Y, Song  DJ, et al. Predictive value of C-reactive protein in response to macrolides in children with macrolide-resistant Mycoplasma pneumoniae pneumonia. Korean J Pediatr. 2014;57:186–92. DOIPubMedGoogle Scholar
  26. Yoo  SJ, Kim  HB, Choi  SH, Lee  SO, Kim  SH, Hong  SB, et al. Differences in the frequency of 23S rRNA gene mutations in Mycoplasma pneumoniae between children and adults with community-acquired pneumonia: clinical impact of mutations conferring macrolide resistance. Antimicrob Agents Chemother. 2012;56:6393–6. DOIPubMedGoogle Scholar
  27. Yoon  IA, Hong  KB, Lee  HJ, Yun  KW, Park  JY, Choi  YH, et al. Radiologic findings as a determinant and no effect of macrolide resistance on clinical course of Mycoplasma pneumoniae pneumonia. BMC Infect Dis. 2017;17:402. DOIPubMedGoogle Scholar
  28. Wu  HM, Wong  KS, Huang  YC, Lai  SH, Tsao  KC, Lin  YJ, et al. Macrolide-resistant Mycoplasma pneumoniae in children in Taiwan. J Infect Chemother. 2013;19:782–6. DOIPubMedGoogle Scholar
  29. Wu  PS, Chang  LY, Lin  HC, Chi  H, Hsieh  YC, Huang  YC, et al. Epidemiology and clinical manifestations of children with macrolide-resistant Mycoplasma pneumoniae pneumonia in Taiwan. Pediatr Pulmonol. 2013;48:904–11. DOIPubMedGoogle Scholar
  30. Yang  TI, Chang  TH, Lu  CY, Chen  JM, Lee  PI, Huang  LM, et al. Mycoplasma pneumoniae in pediatric patients: Do macrolide-resistance and/or delayed treatment matter? J Microbiol Immunol Infect. 2019;52:329–35. DOIPubMedGoogle Scholar
  31. Lee  JK, Lee  JH, Lee  H, Ahn  YM, Eun  BW, Cho  EY, et al. Clonal expansion of macrolide-resistant sequence type 3 Mycoplasma pneumoniae, South Korea. Emerg Infect Dis. 2018;24:1465–71. DOIPubMedGoogle Scholar
  32. Tanaka  T, Oishi  T, Miyata  I, Wakabayashi  S, Kono  M, Ono  S, et al. Macrolide-resistant Mycoplasma pneumoniae infection, Japan, 2008–2015. Emerg Infect Dis. 2017;23:1703–6. DOIPubMedGoogle Scholar
  33. Katsukawa  C, Kenri  T, Shibayama  K, Takahashi  K. Genetic characterization of Mycoplasma pneumoniae isolated in Osaka between 2011 and 2017: Decreased detection rate of macrolide-resistance and increase of p1 gene type 2 lineage strains. PLoS One. 2019;14:e0209938. DOIPubMedGoogle Scholar
  34. Suzuki  Y, Seto  J, Shimotai  Y, Itagaki  T, Katsushima  Y, Katsushima  F, et al. Polyclonal spread of multiple genotypes of Mycoplasma pneumoniae in semi-closed settings in Yamagata, Japan. J Med Microbiol. 2019;68:785–90. DOIPubMedGoogle Scholar
  35. Pereyre  S, Charron  A, Hidalgo-Grass  C, Touati  A, Moses  AE, Nir-Paz  R, et al. The spread of Mycoplasma pneumoniae is polyclonal in both an endemic setting in France and in an epidemic setting in Israel. PLoS One. 2012;7:e38585. DOIPubMedGoogle Scholar
  36. Ando  M, Morozumi  M, Adachi  Y, Ubukata  K, Iwata  S. Multilocus sequence typing of Mycoplasma pneumoniae, Japan, 2002–2016. Emerg Infect Dis. 2018;24:1895–901. DOIPubMedGoogle Scholar
  37. Lluch-Senar  M, Cozzuto  L, Cano  J, Delgado  J, Llórens-Rico  V, Pereyre  S, et al. Comparative “-omics” in Mycoplasma pneumoniae clinical isolates reveals key virulence factors. PLoS One. 2015;10:e0137354. DOIPubMedGoogle Scholar
  38. Zhao  F, Liu  G, Wu  J, Cao  B, Tao  X, He  L, et al. Surveillance of macrolide-resistant Mycoplasma pneumoniae in Beijing, China, from 2008 to 2012. Antimicrob Agents Chemother. 2013;57:1521–3. DOIPubMedGoogle Scholar
  39. Eshaghi  A, Memari  N, Tang  P, Olsha  R, Farrell  DJ, Low  DE, et al. Macrolide-resistant Mycoplasma pneumoniae in humans, Ontario, Canada, 2010-2011. Emerg Infect Dis. 2013;19:1525. DOIPubMedGoogle Scholar
  40. Yang  EA, Kang  HM, Rhim  JW, Kang  JH, Lee  KY. Early corticosteroid therapy for Mycoplasma pneumoniae pneumonia irrespective of used antibiotics in children. J Clin Med. 2019;8:726. DOIPubMedGoogle Scholar
  41. Izumikawa  K. Clinical features of severe or fatal Mycoplasma pneumoniae pneumonia. Front Microbiol. 2016;7:800. DOIPubMedGoogle Scholar
  42. Yamazaki  T, Kenri  T. Epidemiology of Mycoplasma pneumoniae infections in Japan and therapeutic strategies for macrolide-resistant M. pneumoniae. Front Microbiol. 2016;7:693. DOIPubMedGoogle Scholar
  43. Chou  CC, Shen  CF, Chen  SJ, Chen  HM, Wang  YC, Chang  WS, et al.; Infectious Diseases Society of Taiwan; Taiwan Society of Pulmonary and Critical Care Medicine; Medical Foundation in Memory of Dr. Deh-Lin Cheng; Foundation of Professor Wei-Chuan Hsieh for Infectious Diseases Research and Education; CY Lee’s Research Foundation for Pediatric Infectious Diseases and Vaccines; 4th Guidelines Recommendations for Evidence-based Antimicrobial agents use in Taiwan (GREAT) working group. Recommendations and guidelines for the treatment of pneumonia in Taiwan. J Microbiol Immunol Infect. 2019;52:172–99. DOIPubMedGoogle Scholar
  44. Huang  L, Gao  X, Chen  M. Early treatment with corticosteroids in patients with Mycoplasma pneumoniae pneumonia: a randomized clinical trial. J Trop Pediatr. 2014;60:338–42. DOIPubMedGoogle Scholar
  45. Yang  E-A, Kang  H-M, Rhim  J-W, Kang  J-H, Lee  K-Y. Early corticosteroid therapy for Mycoplasma pneumoniae pneumonia irrespective of used antibiotics in children. J Clin Med. 2019;8:726. DOIPubMedGoogle Scholar
  46. Okubo  Y, Michihata  N, Morisaki  N, Uda  K, Miyairi  I, Ogawa  Y, et al. Recent trends in practice patterns and impact of corticosteroid use on pediatric Mycoplasma pneumoniae-related respiratory infections. Respir Investig. 2018;56:158–65. DOIPubMedGoogle Scholar
  47. Teratani  Y, Hagiya  H, Koyama  T, Adachi  M, Ohshima  A, Zamami  Y, et al. Pattern of antibiotic prescriptions for outpatients with acute respiratory tract infections in Japan, 2013-15: a retrospective observational study. Fam Pract. 2019;36:402–9. DOIPubMedGoogle Scholar
  48. Uda  K, Kinoshita  N, Morisaki  N, Kasai  M, Horikoshi  Y, Miyairi  I. Targets for optimizing oral antibiotic prescriptions for pediatric outpatients in Japan. Jpn J Infect Dis. 2019;72:149–59. DOIPubMedGoogle Scholar
  49. Park  J, Han  E, Lee  SO, Kim  D-S. Antibiotic use in South Korea from 2007 to 2014: A health insurance database-generated time series analysis. PLoS One. 2017;12:e0177435. DOIPubMedGoogle Scholar
  50. Meyer Sauteur  PM, Trück  J, van Rossum  AMC, Berger  C. Circulating antibody-secreting cell response during Mycoplasma pneumoniae childhood pneumonia. J Infect Dis. 2020;jiaa062. DOIPubMedGoogle Scholar

Main Article

1All authors contributed equally to this article.

Page created: April 03, 2020
Page updated: June 18, 2020
Page reviewed: June 18, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external